Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M F Fromm

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Biochimica Et Biophysica Acta|January 16, 1999
Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variantsM F Fromm, B Leake, D M Roden, et al.
Circulation|May 1, 1994
An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapyH K Kroemer, M F Fromm, K Bühl, et al.
Pharmacogenetics|December 11, 1999
Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6K Dilger, B Greiner, M F Fromm, et al.
Circulation|February 2, 1999
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]M F Fromm, R B Kim, C M Stein, et al.
Pain|August 1, 1997
Loss of analgesic effect of morphine due to coadministration of rifampinM F Fromm, K Eckhardt, S Li, et al.
British Journal of Clinical Pharmacology|September 1, 1996
Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissueK T Kivistö, G Bookjans, M F Fromm, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 4, 2001
P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxinC Pauli-Magnus, T Mürdter, A Godel, et al.
Clinical Pharmacology and Therapeutics|May 29, 2009
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatinJ E Keskitalo, O Zolk, M F Fromm, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 25, 2000
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoproteinC Pauli-Magnus, O von Richter, O Burk, et al.
International Journal of Clinical Pharmacology and Therapeutics|September 26, 2006
Valdecoxib does not interfere with the CYP2D6 substrate metoprololU Werner, C Lamprecht, D Werner, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Biochimica Et Biophysica Acta|January 16, 1999
Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variantsM F Fromm, B Leake, D M Roden, et al.
Circulation|May 1, 1994
An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapyH K Kroemer, M F Fromm, K Bühl, et al.
Pharmacogenetics|December 11, 1999
Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6K Dilger, B Greiner, M F Fromm, et al.
Circulation|February 2, 1999
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]M F Fromm, R B Kim, C M Stein, et al.
Pain|August 1, 1997
Loss of analgesic effect of morphine due to coadministration of rifampinM F Fromm, K Eckhardt, S Li, et al.
British Journal of Clinical Pharmacology|September 1, 1996
Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissueK T Kivistö, G Bookjans, M F Fromm, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 4, 2001
P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxinC Pauli-Magnus, T Mürdter, A Godel, et al.
Clinical Pharmacology and Therapeutics|May 29, 2009
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatinJ E Keskitalo, O Zolk, M F Fromm, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 25, 2000
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoproteinC Pauli-Magnus, O von Richter, O Burk, et al.
International Journal of Clinical Pharmacology and Therapeutics|September 26, 2006
Valdecoxib does not interfere with the CYP2D6 substrate metoprololU Werner, C Lamprecht, D Werner, et al.
Pageof 6